Pharmacokinetics and pharmacodynamics of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in renal transplantation: A comparison between Japanese and non-Japanese patients

被引：11

作者：

Haba, T

Uchida, K

Katayama, A

Tominaga, Y

Sato, T

Watanabe, I

Inagaki, H

Kimata, T

Goto, K

Morozumi, K

Takeda, A

Takahara, S

Takahashi, K

Oshima, S

机构：

[1] Nagoya Daini Red Cross Hosp, Dept Transplant Surg, Div Hemodialysis, Showa Ku, Nagoya, Aichi 4668650, Japan

[2] Nagoya City Univ, Sch Med, Dept Urol, Nagoya, Aichi 467, Japan

[3] Osaka Univ, Sch Med, Dept Urol, Suita, Osaka 565, Japan

[4] Niigata Univ, Sch Med, Dept Urol, Niigata, Japan

[5] Nagoya Univ, Sch Med, Nagoya, Aichi, Japan

来源：

TRANSPLANTATION PROCEEDINGS | 2001年 / 33卷 / 7-8期

关键词：

D O I：

10.1016/S0041-1345(01)02351-X

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

[No abstract available]

引用

页码：3174 / 3175

页数：2

共 2 条

[1] Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody [J].

Kahan, BD ;

Rajagopalan, PR ;

Hall, M .

TRANSPLANTATION, 1999, 67 (02) :276-284

[2] Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients [J].

Nashan, B ;

Moore, R ;

Amlot, P ;

Schmidt, AG ;

Abeywickrama, K ;

Soulillou, JP .

LANCET, 1997, 350 (9086) :1193-1198

← 1 →